Sana Biotechnology Inc (SANA) News

Form 144 - Report of proposed sale of securities

Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Sana Biotechnology to Present at December 2024 Investor Conferences

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell...

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass...

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...

Form 8-K - Current report